Roxadustat for Patients with Posttransplant Anemia: A Narrative Review

Background: Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are novel oral agents used for renal anemia treatment. Roxadustat, a first-in-class HIF-PHI used for treating anemia in chronic kidney disease patients, has been approved in China, Japan, South Korea, Chile, and Europe. Ro...

Full description

Bibliographic Details

Published in:	Kidney Diseases
Main Authors:	Xiaoxiao Tang, Fei Liu, Qiuyu Li, Jianhua Mao
Format:	Article
Language:	English
Published:	Karger Publishers 2023-11-01
Subjects:	roxadustat hypoxia-inducible factor renal transplantation anemia
Online Access:	https://beta.karger.com/Article/FullText/535071